Contact
Header_1077x260px_About_Profil.jpg

Profil Webinar Series on Diabetes and Obesity

Are you interested in the best glucose clamp method to improve your clinical trial or are you eager to learn about sophisticated devices, such as an artificial pancreas?  Maybe you focus on other topics related to clinical trials, technology or diabetes drug development?

The Profil webinar series brings the information you need right to your doorstep.  Launched in May 2015 our series of webinars covers a wide variety of topics on the diabetes and obesity fields.

Read More

Topics: The Science behind Diabetes, About Profil Germany

Posted by Tatiana Dicenzo on Feb 16, 2017 5:07:00 PM

"Profil World" - The clinical diabetes research newsletter's January 2017 edition

Dear Reader,

We are happy to share with you our winter edition of "Profil World", our newsletter packed with relevant information about clinical trials!

Read More

Topics: About Profil Germany

Posted by Tatiana Dicenzo on Feb 1, 2017 5:15:00 PM

Improved Algorithm for Automated Glucose Clamps

What is Glucose Clamping

The glucose clamp is a method for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of anti-diabetic drugs (e.g. insulin) where the blood glucose (BG) concentration lowering effect is antagonized by variable glucose infusion rates (GIRs). Any device used for automated glucose clamps consists of a glucose sensor and a glucose infusion pump as well as an appropriate algorithm that calculates the amount of glucose solution that has to be infused to keep the blood glucose level at a pre-defined target level. In contrast to manual techniques automated glucose clamps (e.g. using the Biostator) offer the advantage of a bias-free assessment of the pharmacodynamic properties of blood-glucose lowering agents and a minute-by-minute adaptation of glucose infusion rates thereby keeping blood glucose concentrations very close to the clamp target level. However, the Biostator algorithm leads to pronounced oscillations of both BG and GIR requiring mathematical smoothing procedures for the determination of time-related parameters. As ClampArt, our novel automated clamp device, offers the option to modify the clamp algorithm we compared the unmodified Biostator algorithm (UBA) and a potentially improved clamp algorithm (ICA) regarding GIR/BG oscillations and clamp quality.

Read More

Topics: Clinical Trials in Diabetes, About Profil Germany

Posted by Dr. Carsten Benesch on Jan 10, 2017 5:30:00 PM
dr-carsten-benesch

Dr. Tim Heise about Profil's 2016 Science Report

Dear all,

I am very proud to present the Profil Science Report 2016. As in the last years, our Science Report impressively documents the sound scientific expertise of Profil Germany.

With 45 scientific publications (cumulated impact factor of > 187) and more than 100 scientific
presentations at international meetings in 2016 alone, our publication record at Profil Germany can easily
compete with that of many academic institutions.

Read More

Topics: About Profil Germany

Posted by Dr. Tim Heise on Dec 23, 2016 2:44:50 PM
dr-tim-heise

Liver first ? Part III: Medical Needs

In part II and part I of this series you read about the lessons learnt from preclinical work with respect to NASH and NAFLD. In this last part we will look at the medical needs, possible interventions and clinical trials in this area. Enjoy reading and don't forget to register for our monthly blog mailer (to the right of this page) so you won't miss future posts. 

Medical needs

Lifestyle interventions. Although lifestyle changes have been recognised to be a cornerstone in the prevention of diabetes, fatty liver, NASH and cardiovascular disease (Barb et al., 2016) sustainable regimes are difficult to implement and often hamper from a limited compliance of targeted people. There is a general gap between the broad availability of quality information on the impact of livestyle for health promotion and chronic disease prevention on the one hand, and the translation of into behavioural attitudes on the other.

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Dec 9, 2016 5:01:00 PM
prof-dr-freimut-schliess

Liver first ? Part II: NASH and NAFLD

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Dec 1, 2016 12:21:15 PM
prof-dr-freimut-schliess

Modifying insulin kinetics - requirements and limitations (Part 2)

Part 2: Short acting insulins

Rapid and short acting insulins

After carbohydrate ingestion, insulin is released from the beta in accordance to keep blood glucose in a narrow range. Insulin secretion from the beta cell is thereby under the control of glucose concentrations and modulated by several gastrointestinal signals like intestinal hormones (e.g.GIP or GLP-1) or the autonomic nervous system. Due to insufficient insulin release from the beta cells, numerous patients with diabetes mellitus require exogenous insulin substitution and it is always challenging to tailor exogenous insulin treatment to comply with the physiological requirements. In non-diabetic subjects, after a meal, insulin is released quickly in to the portal blood flow to supress the endogenous glucose release from the liver, and to increase glucose uptake in peripheral tissues. To achieve these physiological needs, subcutaneous insulin application reaches several limitations. The slow absorption of insulin from the subcutaneous tissue often causes pronounced postprandial glucose excursions. In addition, the protracted pharmacodynamic activity can increase the risk of hypoglycaemia in between the meals. Fast acting insulin analogues are gradually replacing conventional mealtime insulins because of their faster absorption and more physiological pharmacodynamic profile (figure 1).

Read More
Posted by Prof. Dr. Thomas Forst on Nov 16, 2016 5:00:00 PM
prof-dr-thomas-forst

BIO-Europe 2016: Join the Session on Lifestyle Diseases and Longevity

BIO-Europe

Read More
Posted by Prof. Dr. Freimut Schliess on Nov 4, 2016 12:37:45 PM
prof-dr-freimut-schliess

Glucagon - the rising star in diabetes research (Part 2)

Promising developments in new treatments for diabetes involving glucagon

Role of glucagon action

Glucagon is secreted by the pancreatic alpha cells mainly stimulated by changes in local concentration of glucose, amino acids and insulin and through the autonomic (vegetative) nervous system. Recently, it has been demonstrated that sodium-glucose co-transporter 2 (SGLT-2) is expressed in pancreatic alpha cells, designated for an inhibitory effect on glucagon release in the range of physiological glucose concentrations [1]. The endocrine effects on the liver include the activation on the glucagon receptor (GCGR), a G-protein-coupled receptor (GPCR), and engagement of the GαS and β-arrestin pathways (signalling cascades). Glucagon initiates the increase in the export of glucose from the liver as a result of enhanced glycogenolysis and gluconeogenesis [2, 3, 4, 5].

Read More

Topics: The Science behind Diabetes

Posted by Dr. Ulrike Hövelmann on Oct 21, 2016 5:00:00 PM
dr-ulrike-hövelmann

"Profil World" - Novel clamp method, upcoming webinar with JJ Meier, history of Glucagon research

Welcome to our October edition of the "Profil World" newsletter. We are happy to bring you a newsletter packed with interesting articles for the diabetes research-minded. At the same time, we are gearing up for the conference season and look forward to meeting our sponsors at events such as Obesity Week, BioEurope, World Congress for Clinical Trials in Diabetes and others. Let us know if you would like to meet for a chat. But for now, enjoy reading. 

Read More
Posted by Dr. Lars Bochmann on Oct 5, 2016 5:00:00 PM
dr-lars-bochmann